# Clinical Information and Prognosis of High-risk Luminal Breast Cancer Subjects Eligible for the MonarhE Study

## TL;DR

This study analyzes clinical data and prognosis of high-risk luminal breast cancer patients eligible for the MonarchE trial, focusing on survival outcomes.

## Contribution

The study provides real-world clinical data on high-risk luminal breast cancer patients not previously analyzed in this context.

## Key findings

- The 5-year invasive-disease-free survival rate was 85.0% among participants.
- Neither chemotherapy nor menopausal status significantly affected invasive-disease-free survival.
- Univariate analysis found no factors influencing invasive-disease-free survival.

## Abstract

Luminal breast cancer is the most common breast cancer subtype. Although its prognosis can be good, this type of breast cancer is characterized by a high incidence of late recurrence. However, to the best of our knowledge, there are no publications showing prognostic value regarding the invasive-disease-free survival (IDFS) and distant relapse-free survival in this group in clinical practice. Therefore, this study examined the clinical data and prognosis of patients participating in the MonarchE trial.

This study included patients who underwent surgery at Tokyo Metropolitan Komagome Hospital and whose corresponding prognosis to the Monarch E trial could be followed up.

The total number of participants was 152, of whom 104 (68%) were treated with chemotherapy. Seventy-five patients (49%) were postmenopausal. The IDFS after 5 years was 85.0%. Although IDFS did not differ in terms of the menstrual status, premenopausal patients tended to receive a higher proportion of tamoxifen, and there was a greater number of patients treated with chemotherapy. However, neither chemotherapy nor menstrual statuses were found to affect the IDFS incidence.

Real clinical data applicable to the MonarchE study were examined. Our univariate analysis revealed that there were no factors affecting IDFS.